# Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

> **NCT00044304** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 70 (actual)

## Conditions studied

- Eosinophilic Myeloid Neoplasm
- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT00044304
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2002-09-26
- **Primary completion:** 2023-11-16
- **Final completion:** 2027-03-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044304, "Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00044304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*